1. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial (BEGIN: ADD TO GLP‐1 Study). Issue 7 (2nd May 2016) Authors: Aroda, V. R.; Bailey, T. S.; Cariou, B.; Kumar, S.; Leiter, L. A.; Raskin, P.; Zacho, J.; Andersen, T. H.; Philis‐Tsimikas, A. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 7(2016) Page Start: 663 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co‐formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial. Issue 3 (11th January 2016) Authors: Rodbard, H. W.; Cariou, B.; Pieber, T. R.; Endahl, L. A.; Zacho, J.; Cooper, J. G. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 3(2016) Page Start: 274 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes. Issue 4 (17th November 2015) Authors: Franek, E.; Haluzík, M.; Canecki Varžić, S.; Sargin, M.; Macura, S.; Zacho, J.; Christiansen, J. S. Journal: Diabetic medicine Issue: Volume 33:Issue 4(2016:Apr.) Page Start: 497 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗